Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 14, 2008

Protalix Expands Manufacturing and Research Space in Carmiel, Israel

  • Protalix BioTherapeutics signed a lease for the expansion of its manufacturing and research facility. The extension, located at the company’s facility in Carmiel, Israel, will provide Protalix with approximately three times its current space.

    The site is particularly important in anticipation of the potential commercialization of its lead candidate, prGCD, in a Phase III trial for Gaucher disease, Protalix points out. The term of the lease agreement is seven and a half years. Protalix has the option to extend the life of the lease for up to 15 additional years.

    “In light of the progress we have made to date in our prGCD program, we determined that we should commence the expansion of our current facility,” says Yossi Maimon, CFO. “Our expanded facility will provide us with the space and capacity required to bring prGCD to market and meet the anticipated demand for the drug following its anticipated approval by the United States Food and Drug Administration while continuing to advance the research of the additional product candidates in our development pipeline.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »